T1000	Speculation 1429 1432	may
E1000	Speculation:T1000 Scope:T1001
T1001	Span 1423 1487	which may be obscured by combining them into "MyAg positive ALL"
T1002	Speculation 312 319	unclear
E1001	Speculation:T1002 Scope:T1003
T1003	Span 282 319	its regulating mechanisms are unclear
T1004	Negation 1853 1860	without
E1002	Negation:T1004 Scope:T1005
T1005	Span 1853 1879	without surface expression
T1006	Negation 1542 1545	not
E1003	Negation:T1006 Scope:T1007
T1007	Span 1502 1626	unlike other MyAgs, CD66c expression is not shifted from the onset of ALL to relapse (n = 39, time to relapse 0.3-5.3 years)
T1008	Negation 1912 1915	nor
E1004	Negation:T1008 Scope:T1009
T1009	Span 1912 1939	nor by Western blot in vivo
T1010	Negation 1884 1887	not
E1005	Negation:T1010 Scope:T1011
T1011	Span 1884 1939	not found by flow cytometry nor by Western blot in vivo
T1012	Negation 1951 1953	no
E1006	Negation:T1012 Scope:T1013
T1013	Span 1951 1986	no prognostic significance of CD66c
T1014	Speculation 1666 1675	suggested
E1007	Speculation:T1014 Scope:T1015
T1015	Span 1637 1675	opposite has previously been suggested
T1016	Speculation 2140 2146	notion
E1008	Speculation:T1016 Scope:T1017
T1017	Span 2140 2246	notion we show that different MyAgs in lymphoblastic leukemia represent different biological circumstances
T1018	Negation 2051 2054	nor
E1009	Negation:T1018 Scope:T1019
T1019	Span 2051 2093	nor an association with known risk factors
